Could Nucleolin and Nucleophosmin Levels Be Prognostic Indicators in Non-Small Cell Lung Cancer?

Basit Öğe Kaydı
dc.authorscopusid58102138800
dc.authorscopusid54386737900
dc.authorscopusid34868115100
dc.contributor.authorAkın, Gül
dc.contributor.authorEsbah, O.
dc.contributor.authorEröz, Recep
dc.date.accessioned2023-07-26T11:55:24Z
dc.date.available2023-07-26T11:55:24Z
dc.date.issued2022
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractAim: Lung cancer is the leading cause of mortality from cancer across the world. In this study, the use of serum nucleolin (NCL) and nucleophosmin (NPM1) levels as a marker in the diagnosis, prognosis and treatment response evaluation in lung cancer was investigated. Materials and Method: NCL and NPM1 levels of serum samples taken before chemotherapy and after 3-4 courses of chemotherapy from the control group and the patients diagnosed with lung cancer were studied using ELISA method. Results: Serum NCL and NPM1 levels of the patients were higher than of the controls (p = 0.085 for NCL, p = 0.000 for NPM1). NCL and NPM1 levels by histopathologic type were significantly higher in adenocarcinoma than in squamous cell carcinoma (p < 0.05 for each). In view of the treatment responses to chemotherapeutic agents, there was a statistically insignificant difference between the values before and after chemotherapy (p > 0.05 for each). Conclusion: High serum NCL and NPM1 levels were found to correlate with poor prognosis, poor treatment response and low survival rate. It can be concluded that serum NCL and NPM1 levels in lung cancer can be used as diagnostic and prognostic markers for the disease. © 2022 Sciendo. All rights reserved.en_US
dc.identifier.doi10.5937/afmnai39-35741
dc.identifier.endpage442en_US
dc.identifier.issn0351-6083
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85148040106en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage433en_US
dc.identifier.urihttps://doi.org/10.5937/afmnai39-35741
dc.identifier.urihttps://hdl.handle.net/20.500.12684/13065
dc.identifier.volume39en_US
dc.identifier.wosWOS:000954602100004en_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorAkın, Gül
dc.institutionauthorEşbah, Onur
dc.language.isoenen_US
dc.publisherUniversity of Nis, Faculty of Medicineen_US
dc.relation.ispartofActa Facultatis Medicae Naissensisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectcanceren_US
dc.subjectnucleolinen_US
dc.subjectnucleophosminen_US
dc.subjectnucleolinen_US
dc.subjectnucleophosminen_US
dc.subjectadenocarcinomaen_US
dc.subjectadulten_US
dc.subjectArticleen_US
dc.subjectcancer chemotherapyen_US
dc.subjectcancer diagnosisen_US
dc.subjectcancer growthen_US
dc.subjectcancer prognosisen_US
dc.subjectcancer sizeen_US
dc.subjectcancer therapyen_US
dc.subjectclinical articleen_US
dc.subjectcorrelation analysisen_US
dc.subjectenzyme linked immunosorbent assayen_US
dc.subjecthistopathologyen_US
dc.subjecthumanen_US
dc.subjecthuman tissueen_US
dc.subjectlymph node metastasisen_US
dc.subjectmiddle ageden_US
dc.subjectmortalityen_US
dc.subjectnon small cell lung canceren_US
dc.subjectoverall survivalen_US
dc.subjectsquamous cell carcinomaen_US
dc.subjectsurvival rateen_US
dc.subjecttreatment responseen_US
dc.titleCould Nucleolin and Nucleophosmin Levels Be Prognostic Indicators in Non-Small Cell Lung Cancer?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
13065.pdf
Boyut:
458.17 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu